Video

Medicare Part D and Oncology

Author(s):

Lauren Santye, Assistant Editor

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com
Psychiatric pharmacist and patient -- Image credit: NanSan | stock.adobe.com
Psychiatric pharmacist -- Image credit: HBS | stock.adobe.com
Hematology -- Image credit: DIgilife | stock.adobe.com
Image credit: Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Related Content
Diffuse large B cell lymphoma (DLBCL) -- Image credit: SuriyaPhoto | stock.adobe.com
July 18th 2025

FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL

Gillian McGovern, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost
July 18th 2025

NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost

Alana Hippensteele, Lead Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
NCCN Flash Update: Ovarian Cancer Guidelines Version 3.2025 Released With Maintenance Therapy Adjustment for HR-Deficiency
July 18th 2025

NCCN Flash Update: Ovarian Cancer Guidelines Version 3.2025 Released With Maintenance Therapy Adjustment for HR-Deficiency

Alana Hippensteele, Lead Editor
Study Highlights Filgrastim Savings Potential With Biosimilars
July 18th 2025

Study Highlights Filgrastim Savings Potential With Biosimilars

Ethan Nolin-Halpern, PharmD Candidate